Making cancer treatment accessible for everyone
An innovative approach helped us develop and launch an affordable generic version of Azacitidine in the US
An innovative approach helped us develop and launch an affordable generic version of Azacitidine in the US
Our state-of-the-art R&D centres across the globe offer a wide-ranging suite of services including synthetic organic chemistry, formulations development, IP management and biopharmaceutics. For our industrial customers, we offer solutions with regard to starting material, intermediates, active ingredients and finished-dosage forms.
Our R&D team is devoted to improving patients’ lives and contributing to the ever-evolving world of holistic healthcare. We work hard to develop complex products and aim at being first to market.
We have state-of-the art research and development centres in India, Europe and the US. They give us the means to handle advanced physico-chemical and biological characterization with ease. We also have some of the brightest scientists and researchers in the world working in tandem to create complex pharmaceutical ingredients, advanced particle engineering solutions, and complex products or dosage forms.
Centres in: Hyderabad, Bangalore, USA, UK, Netherlands
Generic versions of innovator drugs raise the possibility of every patient having access to quality healthcare because of their affordability. Our team ambitiously strives to develop high-quality generics, bringing expensive medicines within the reach of patients globally.
Product portfolio: Novel crystalline and amorphous forms, Semi-synthetic APIs, Chirals, Prostaglandins, peptides and carbohydrates, Nano particle-based products
We have end-to-end research capabilities in developing vaccines, blood components, cells, allergens, genes, tissues and recombinant proteins. Our Centres of Excellence in Hyderabad, Basel and Princeton have state-of-the-art technology in cell line and process development, and robust capabilities in bio-analytics. We have extensive experience with complex healthy volunteer and patient studies. Our teams are well-versed in liaising with key regulatory agencies around the world.
We focus on developing novel differentiated formulations to be used primarily in the dermatology and neurology markets. Our aim is to develop affordable products and design different delivery technologies to help patients manage their diseases better.
Over the years, our team has developed the ability to handle advanced physico-chemical and biological characterisations such as particle morphology, sequencing, and secondary and tertiary structures with ease. We also have the capability to utilise advanced particle engineering solutions and complex scale-ups (such as those using microsphere and liposomal technologies) to create complex products and dosage forms.
